share_log

Vertex Pharmaceuticals | 8-K: Vertex Reports Second Quarter 2024 Financial Results

Vertex Pharmaceuticals | 8-K: Vertex Reports Second Quarter 2024 Financial Results

福泰製藥 | 8-K：Vertex 公佈 2024 年第二季度財務業績
美股SEC公告 ·  2024/08/02 04:07

Moomoo AI 已提取核心訊息

Vertex Pharmaceuticals reported Q2 2024 product revenues of $2.65 billion, up 6% YoY, driven by strong TRIKAFTA/KAFTRIO performance. The company raised its full-year 2024 product revenue guidance to $10.65-$10.85 billion. Combined GAAP R&D and SG&A expenses were $1.3 billion, while acquired IPR&D expenses reached $4.4 billion due to the Alpine Immune Sciences acquisition.The FDA granted Priority Review for two key products: the vanzacaftor triple combination therapy for cystic fibrosis with a PDUFA date of January 2, 2025, and suzetrigine for moderate-to-severe acute pain with a PDUFA date of January 30, 2025. The company has also received validation of vanzacaftor triple MAA submissions in the EU and UK.Vertex continues to advance its broad pipeline, including CASGEVY launches for SCD and TDT with over 35 authorized treatment centers activated globally. The company reported strong cash position of $10.2 billion as of June 30, 2024, despite the Alpine acquisition impact. Multiple clinical milestones are expected in H2 2024 across various programs including pain, kidney diseases, and type 1 diabetes.
Vertex Pharmaceuticals reported Q2 2024 product revenues of $2.65 billion, up 6% YoY, driven by strong TRIKAFTA/KAFTRIO performance. The company raised its full-year 2024 product revenue guidance to $10.65-$10.85 billion. Combined GAAP R&D and SG&A expenses were $1.3 billion, while acquired IPR&D expenses reached $4.4 billion due to the Alpine Immune Sciences acquisition.The FDA granted Priority Review for two key products: the vanzacaftor triple combination therapy for cystic fibrosis with a PDUFA date of January 2, 2025, and suzetrigine for moderate-to-severe acute pain with a PDUFA date of January 30, 2025. The company has also received validation of vanzacaftor triple MAA submissions in the EU and UK.Vertex continues to advance its broad pipeline, including CASGEVY launches for SCD and TDT with over 35 authorized treatment centers activated globally. The company reported strong cash position of $10.2 billion as of June 30, 2024, despite the Alpine acquisition impact. Multiple clinical milestones are expected in H2 2024 across various programs including pain, kidney diseases, and type 1 diabetes.
福泰製藥報告2024年第二季度產品營業收入爲26.5億美金，同比增長6%，主要受益於TRIKAFTA/KAFTRIO的強勁表現。公司將2024年全年產品營業收入的指導提高至106.5億-108.5億美金。綜合GAAP研發和銷售、管理費用爲13億美金，同時由於收購Alpine Immune Sciences，獲得的知識產權研發費用達到44億美金。FDA對兩個關鍵產品給予優先審評：用於囊性纖維化的vanzaftor三重組合療法，其PDUFA日期爲2025年1月2日，以及用於中度至重度急性疼痛的suzetrigine，其PDUFA日期爲2025年1月30日。公司還獲得了EU和英國vanzaftor三...展開全部
福泰製藥報告2024年第二季度產品營業收入爲26.5億美金，同比增長6%，主要受益於TRIKAFTA/KAFTRIO的強勁表現。公司將2024年全年產品營業收入的指導提高至106.5億-108.5億美金。綜合GAAP研發和銷售、管理費用爲13億美金，同時由於收購Alpine Immune Sciences，獲得的知識產權研發費用達到44億美金。FDA對兩個關鍵產品給予優先審評：用於囊性纖維化的vanzaftor三重組合療法，其PDUFA日期爲2025年1月2日，以及用於中度至重度急性疼痛的suzetrigine，其PDUFA日期爲2025年1月30日。公司還獲得了EU和英國vanzaftor三重MAA提交的驗證。福泰繼續推進其廣泛的管線，包括爲SCD和TDt推出的CASGEVY，在全球激活了超過35個授權治療中心。儘管受到Alpine收購的影響，公司截至2024年6月30日報告的現金狀況強勁，達到了102億美金。預計在2024年下半年將有多個臨牀里程碑在包括疼痛、腎臟疾病和1型糖尿病等多個項目中實現。

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    Corcept醫療
    CORT
    -- 100.470
    bluebird bio
    BLUE
    -- 5.240
    Citius Pharmaceuticals
    CTXR
    -- 1.9299
    NLS Pharmaceutics
    NLSP
    -- 1.4504
    Entero Therapeutics
    ENTO
    -- 0.526
    解鎖完整榜單
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。
    熱門討論
    FOMC維持利率但不確定性高企：美股後市走向如何？
    🎙️討論 1. 美聯儲強調政策路徑存在「高度不確定性」，你更關注利率預期變化還是經濟數據對市場的短期影響？ 2. 若核心通脹維持高位，哪類板塊更具交易機會——防禦型股票還是科技成長股？ 展开
    聯邦公開市場委員會新聞發佈會，2025年3月19日